Aliakbari F, Shabani A, Bardania H, Eslampanah Seyedi HA, Mohammad-Beigi H, Tayaranian Marvian A et al (2017) Neurotoxicity of pre-incubated alpha-synuclein with neutral nanoliposomes on PC12 and SHSY5Y cell lines. Scientia Iranica 24(6):3542–3553

Google Scholar 

Aliakbari F, Mohammad-Beigi H, Abbasi S, Rezaei‐Ghaleh N, Lermyte F, Parsafar S et al (2021) Multiple protective roles of Nanoliposome‐Incorporated Baicalein against Alpha‐Synuclein aggregates. Adv Funct Mater 31(7):2007765

Article  CAS  Google Scholar 

Allegritti E, Battista S, Maggi MA, Marconi C, Galantini L, Giansanti L (2023) Novel liposomal formulations for protection and delivery of levodopa: Structure-properties correlation. Int J Pharm 643:123230

Article  PubMed  CAS  Google Scholar 

Angelova A, Angelov B (2017) Dual and multi-drug delivery nanoparticles towards neuronal survival and synaptic repair. Neural Regeneration Res 12(6):886–889

Article  CAS  Google Scholar 

Ben-Shlomo Y, Darweesh S, Llibre-Guerra J, Marras C, San Luciano M, Tanner C (2024) The epidemiology of parkinson’s disease. Lancet 403(10423):283–292

Article  PubMed  PubMed Central  Google Scholar 

Boer DE, van Smeden J, Bouwstra JA, Aerts JM (2020) Glucocerebrosidase: functions in and beyond the lysosome. J Clin Med 9(3):736

Article  PubMed  PubMed Central  CAS  Google Scholar 

Burré J, Sharma M, Südhof TC (2018) Cell biology and pathophysiology of α-synuclein. Cold Spring Harbor Perspect Med 8(3):a024091

Article  Google Scholar 

Calabresi P, Mechelli A, Natale G, Volpicelli-Daley L, Di Lazzaro G, Ghiglieri V (2023) Alpha-synuclein in parkinson’s disease and other synucleinopathies: from overt neurodegeneration back to early synaptic dysfunction. Cell Death Dis 14(3):176

Article  PubMed  PubMed Central  Google Scholar 

Chinchilla-Cárdenas DJ, Cruz-Méndez JS, Petano-Duque JM, García RO, Castro LR, Lobo-Castañón MJ et al (2024) Current developments of SELEX technologies and prospects in the aptamer selection with clinical applications. J Genetic Eng Biotechnol 22(3):100400

Article  Google Scholar 

Choi ML, Chappard A, Singh BP, Maclachlan C, Rodrigues M, Fedotova EI et al (2022) Pathological structural conversion of α-synuclein at the mitochondria induces neuronal toxicity. Nat Neurosci 25(9):1134–1148

Article  PubMed  PubMed Central  CAS  Google Scholar 

Costa HN, Esteves AR, Empadinhas N, Cardoso SM (2023) Parkinson’s disease: a multisystem disorder. Neurosci Bull 39(1):113–124

Article  PubMed  Google Scholar 

Dias V, Junn E, Mouradian MM (2013) The role of oxidative stress in parkinson’s disease. J Parkinson’s Disease 3(4):461–491

Article  CAS  Google Scholar 

Dong-Chen X, Yong C, Yang X, Chen-Yu S, Li-Hua P (2023) Signaling pathways in parkinson’s disease: molecular mechanisms and therapeutic interventions. Signal Transduct Target Therapy 8(1):73

Article  Google Scholar 

Elgohary MK, Elkotamy MS, Alkabbani MA, Abdel-Aziz HA (2024) Fenamates and ibuprofen as foundational components in the synthesis of innovative, targeted COX-2 anti-inflammatory drugs, undergoing thorough biopharmacological assessments and in-silico computational studies. Bioorg Chem 147:107393

Article  PubMed  CAS  Google Scholar 

Feraco P, Gagliardo C, La Tona G, Bruno E, D’angelo C, Marrale M et al (2021) Imaging of substantia Nigra in parkinson’s disease: a narrative review. Brain Sci 11(6):769

Article  PubMed  PubMed Central  CAS  Google Scholar 

Gadde S (2015) Multi-drug delivery nanocarriers for combination therapy. MedChemComm 6(11):1916–1929

Article  CAS  Google Scholar 

Guo Y-y, Huang L, Zhang Z-p (2020) Fu D-h. Strategies for precise engineering and conjugation of antibody targeted-nanoparticles for cancer therapy. Curr Med Sci 40(3):463–473

Article  PubMed  CAS  Google Scholar 

Jagaran K, Singh M (2022) Lipid nanoparticles: promising treatment approach for parkinson’s disease. Int J Mol Sci 23(16):9361

Article  PubMed  PubMed Central  CAS  Google Scholar 

Jebali A, Behzadi A, Rezapor I, Jasemizad T, Hekmatimoghaddam SH, Halvani GH et al (2015) Adsorption of humic acid by amine-modified nanocellulose: an experimental and simulation study. Int J Environ Sci Technol 12:45–52

Article  CAS  Google Scholar 

Jebali A, Rashidi M, Keikha R, Daliri K, Outeiro TF (2021) Novel multifunctional nanoliposomes inhibit α-synuclein fibrillization, attenuate microglial activation, and silence the expression of SNCA gene. Neurologia

Li X, Koudstaal W, Fletcher L, Costa M, van Winsen M, Siregar B et al (2019) Naturally occurring antibodies isolated from PD patients inhibit synuclein seeding in vitro and recognize lewy pathology. Acta Neuropathol 137:825–836

Article  PubMed  PubMed Central  CAS  Google Scholar 

Liu J, Gao D, Hu D, Lan S, Liu Y, Zheng H et al (2023) Delivery of biomimetic liposomes via meningeal lymphatic vessels route for targeted therapy of parkinson’s disease. Research 6:0030

Article  PubMed  PubMed Central  CAS  Google Scholar 

Marogianni C, Sokratous M, Dardiotis E, Hadjigeorgiou GM, Bogdanos D, Xiromerisiou G (2020) Neurodegeneration and inflammation—an interesting interplay in parkinson’s disease. Int J Mol Sci 21(22):8421

Article  PubMed  PubMed Central  CAS  Google Scholar 

McConnell EM, Chan D, Ventura K, Callahan JP, Harris K, Hunt VH et al (2024) Selection of DNA aptamers that prevent the fibrillization of α-synuclein protein in cellular and mouse models. Mol Therapy-Nucleic Acids. 35(3)

Mogharbel BF, Cardoso MA, Irioda AC, Stricker PEF, Slompo RC, Appel JM et al (2022) Biodegradable nanoparticles loaded with Levodopa and Curcumin for treatment of parkinson’s disease. Molecules 27(9):2811

Article  PubMed  PubMed Central  CAS  Google Scholar 

Monge-Fuentes V, Biolchi Mayer A, Lima MR, Geraldes LR, Zanotto LN, Moreira KG et al (2021) Dopamine-loaded nanoparticle systems circumvent the blood–brain barrier restoring motor function in mouse model for parkinson’s disease. Sci Rep 11(1):15185

Article  PubMed  PubMed Central  CAS  Google Scholar 

Moreira R, Nóbrega C, de Almeida LP, Mendonça L (2024) Brain-targeted drug delivery-nanovesicles directed to specific brain cells by brain-targeting ligands. J Nanobiotechnol 22(1):260

Article  CAS  Google Scholar 

Ntetsika T, Papathoma P-E, Markaki I (2021) Novel targeted therapies for parkinson’s disease. Mol Med 27:1–20

Article  Google Scholar 

Ozturk M, Nilsen-Hamilton M, Ilgu M (2021) Aptamer applications in neuroscience. Pharmaceuticals 14(12):1260

Article  PubMed  PubMed Central  CAS  Google Scholar 

Paliwal H, Prajapati BG (2025) Srichana T. Nanotechnology-based drug delivery systems for the treatment of neurodegenerative disorders. Nanomedicine for Neurodegenerative Disorders: Selective Treatment Strategies 147

Pasha S, Gupta K (2010) Various drug delivery approaches to the central nervous system. Expert Opin Drug Deliv 7(1):113–135

Article  PubMed  CAS  Google Scholar 

Pereira JB, Kumar A, Hall S, Palmqvist S, Stomrud E, Bali D et al (2023) DOPA decarboxylase is an emerging biomarker for parkinsonian disorders including preclinical lewy body disease. Nat Aging 3(10):1201–1209

Article  PubMed  PubMed Central  CAS  Google Scholar 

Preetam S, Jonnalagadda S, Kumar L, Rath R, Chattopadhyay S, Alghamdi BS et al (2023) Therapeutic potential of lipid nanosystems for the treatment of parkinson’s disease. Ageing Res Rev 89:101965

Article  PubMed  CAS  Google Scholar 

Pringsheim T, Jette N, Frolkis A, Steeves TD (2014) The prevalence of parkinson’s disease: a systematic review and meta-analysis. Mov Disord 29(13):1583–1590

Article  PubMed  Google Scholar 

Roy R, Paul R, Bhattacharya P, Borah A (2023) Combating dopaminergic neurodegeneration in parkinson’s disease through nanovesicle technology. ACS Chem Neurosci 14(16):2830–2848

Article  PubMed